Top Story

Grazoprevir plus ribavirin linked to rapid, sustained suppression of HCV RNA

July 1, 2016

The combination of grazoprevir plus ribavirin for 12 or 24 weeks demonstrated fast and sustained suppression of hepatitis C virus RNA in treatment-naive patients with hepatitis C virus genotype 1 infection, according to study results.

“The aim of the present proof-of-concept study was to evaluate the interferon free, single direct-acting antiviral regimen of [grazoprevir] plus [ribavirin] in patients with HCV [genotype 1] infection,” Ed Gane, MB ChB, MD, FRACP, MNZM, of Auckland Clinical Studies in New Zealand, and colleagues wrote. “Based on the response guided treatment (RGT) regimens used with first-generation protease inhibitors, this pilot study (the C-SPIRIT study) was designed to include an RGT treatment arm and also to assess the potential for a minimal drug regimen in patients with [genotype 1] HCV infection considered ‘easy to cure.’”

Top online hepatology stories posted in the last month

July 1, 2016
Healio.com/Hepatology compiled a list of the top 10 news reports on hepatology posted from June 1 to June 30. Healio.com/Hepatology and HCV Next readers were…
Meeting News Coverage

ARQ 087 appears safe for treatment of intrahepatic cholangiocarcinoma

June 30, 2016
ARQ 087, a multi-kinase inhibitor designed to inhibit fibroblast growth factor receptor, displayed a favorable safety profile when administered as monotherapy to…
Health Care Legislative and Regulatory Update

Case to proceed against clinic for alleged false billing for tonography

June 30, 2016
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of…

AGA meets with CMS, Congress to support alternative payment models under MACRA

June 30, 2016
The AGA met with CMS and Congress this week to express its support for specialty alternative payment models under the Medicare Access and Chip Reauthorization Act of…
More News Headlines »

Rapid Response from Barcelona: New Data in HCV Treatment

This activity is supported by an educational grant from AbbVie and Merck & Co., Inc.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
GI Bookshelf

Question 21: What Colonic Infections Are Associated with AIDS

From Curbside Consultation of the Colon: 49 Clinical Questions
More »
Highlights from International Liver Congress

Highlights from International Liver Congress


VIDEO: Patients with HIV, HCV face risk for re-infection following antiviral treatment

May 27, 2016
More »
Current Issues Current Issues
View the Current Issue
HCV Next